Utah Medical Products (UTMD) Q3 2026 earnings review
Utah Medical profit rises on accounting, but device sales drop
Utah Medical Products, a maker of specialty surgical and neonatal devices, reported higher profit only because prior-year accounting charges disappeared while device demand fell. Underlying sales from businesses owned a year ago dropped 18% by our math, as a steep slump in Filshie contraceptive clips compounded the loss of its two largest customers. A newly acquired UK supplier and a replacement Chinese distributor softened the top-line drop to 12%, while the end of a 15-year intangible amortization schedule lifted profit per share.
| Sales from businesses owned a year ago | $8.00M -18.5% from a year ago (by our math) |
|---|---|
| Reported revenue | $8.62M -12.1% from a year ago (includes Orion) |
| Profit per share | $0.88 +6.8% from a year ago |
| Full-year revenue outlook | Cut to -7% implies +10% growth in Q4 by our math |
⚖️ Verdict: 🔴 Bearish
The story got worse because demand shrank in core hospital lines while new biopharma orders arrived slower than management expected, forcing the company to cut its full-year sales plan to a 7% decline. Keeping factory staff in place for those delayed orders pushed inventories up 30%, and two Filshie Clip lawsuits are now heading toward trial in 2027. One bright spot: by our math, the full-year outlook points to fourth-quarter revenue rising 10% as prior-year customer losses finally lap.
The question now is whether the third-quarter drop in Filshie clips and neonatal devices was a temporary ordering pause or a lasting loss of hospital demand. If hospitals merely delayed purchases, a full quarter of Orion Medical and reorders from the new China partner will return the company to growth; if demand is shrinking, excess factory inventory will hurt future margins. Fourth-quarter results against the implied $10 million sales target will tell.
🐂 Bull Case
Orion Deal and New China Partner Cushion Lost Accounts
Utah Medical Products lost its two largest customers entering 2026: biopharma sensor buyer PendoTECH and a Chinese distributor of blood pressure monitoring (BPM) kits. To plug that gap, the UK subsidiary bought Orion Medical Supplies at the end of August for $5.0 million and signed a replacement distributor in China.
- Orion Medical contribution: $619 thousand in September sales
- New China BPM distributor: $195 thousand in initial third-quarter shipments
- New biopharma customers: $116 thousand in the quarter and $327 thousand over nine months
These moves matter because "the 2026 growth in new biopharm sales has been slower than expected", the company said. The device maker noted regarding the new Chinese partner that "This distributor might eventually match the prior distributor’s demand", while a full quarter of Orion will lift fourth-quarter revenue.
What to watch: fourth-quarter reorder rates from the new Chinese distributor and three-month revenue from Orion. Repeat orders in China would show that the third-quarter shipment was ongoing hospital demand rather than one-time inventory stocking.
Lapping Customer Losses Points to Fourth-Quarter Growth
The medical device maker spent the first three quarters of 2026 comparing against heavy prior-year shipments to PendoTECH and its former Chinese distributor. Those two accounts generated $2.42 million in the first nine months of 2025, but their combined purchases dropped to just $35 thousand in the fourth quarter of 2025.
Because that comparison obstacle disappears next quarter, Utah Medical Products issued an outlook for "a total year 2026 consolidated sales decline close to 7%". By our math, hitting that full-year target requires fourth-quarter revenue to rise about 10% from a year ago to $10.0 million, ending a six-quarter streak of shrinking top-line results.
What to watch: fourth-quarter consolidated sales against the $10.0 million level implied by the full-year outlook. Falling short even with a full three months of Orion revenue would mean weakness in older hospital and surgical product lines is worsening.
🐻 Bear Case
Accounting Relief Lifted Operating Profit as Cash Earnings Fell
Headline operating income rose 7.0% from a year ago to $2.80 million, lifting the operating margin by 5.8 percentage points to 32.4%. However, that improvement came entirely from general and administrative overhead, which fell by 7.5 percentage points of revenue to 16.0% after two non-operating charges from last year disappeared.
- Femcare intangible amortization: $0, down from $536 thousand a year ago after the 15-year schedule ended
- China bad-debt write-off: $0, compared with $395 thousand in the prior-year quarter
- EBITDA excluding one-offs: $3.74 million, down 10.4% from $4.17 million a year ago
Management said its EBITDA measure confirms its ability to sustain high performance, but the 10.4% drop in that exact metric shows cash earnings shrank alongside revenue. Stripping out intangible amortization and last year's bad-debt charge, third-quarter operating profit fell 20.4% by our math.
What to watch: fourth-quarter EBITDA excluding one-offs, which removes the distortion of the completed Femcare amortization. A fourth straight quarterly drop would show that new revenue from Orion and China is not yet replacing the cash profit of lost accounts.
Underlying Sales Dropped Faster as Filshie Demand Slumped
Reported revenue fell 12.1% to $8.62 million, but that headline includes one month of sales from newly acquired Orion Medical. Sales from businesses owned a year ago fell 18.5% to $8.00 million by our math, a steeper drop than the 10.2% decline in the first quarter and 14.3% in the second.
- Worldwide Filshie Clip System: down 32.7%, or $805 thousand, from a year ago
- US domestic Filshie sales: $656 thousand, down 44.9% by our math after rising in the first half
- Domestic direct non-Filshie devices: down $449 thousand, led by neonatal intensive care products
The Filshie Clip System, a surgical contraceptive device, accounted for two-thirds of the consolidated top-line decline this quarter. Because the company manufactures Filshie clips at its own plant in Ireland, lower shipments also left factory overhead unabsorbed and hurt profitability.
What to watch: fourth-quarter domestic and international Filshie Clip sales in the annual report. Another double-digit drop would indicate that surgical contraception demand is shrinking structurally rather than suffering a one-quarter ordering pause.
Idle Factory Staff and Unsold Goods Weighed on Margins
Gross margin slipped 1.0 percentage point from a year ago to 56.1% as cost of goods sold rose to 43.9% of revenue. Utah Medical Products said it "retained the same previous labor and overhead staffing that it previously had in order to support the anticipated substantial new growth in biopharma control device manufacturing".
To keep those workers busy while orders lagged, the manufacturer "intentionally increased WIP/FG goods inventory balances in order to keep productivity up during 9M 2026 lower sales activity". That decision pushed inventories up 30.2% from a year ago to $10.57 million and cut inventory turnover from 2.0 times at year-end to 1.6 times.
What to watch: ending inventory balances and gross margin in the fourth-quarter report. If biopharma orders do not pick up, the company will eventually have to slow factory production and absorb the idle overhead directly on its income statement.
Two Filshie Clip Lawsuits Now Head Toward Trial
Utah Medical Products has spent years defending product liability lawsuits in the United States over its Filshie Clip contraceptive device. Through the first quarter of 2026, the company had won dismissals in 15 of the 19 courts where plaintiffs filed cases, and it projected lower legal spending this year assuming no case went to trial.
This quarter, the device maker warned that "in two of the remaining four courts (out of nineteen), cases will apparently be going to trial in 2027". Although third-quarter US litigation spending fell by $186 thousand from a year ago to $203 thousand, nine-month legal costs are still up $160 thousand to $1.14 million, or 4.4% of revenue.
What to watch: summary judgment rulings in the other two courts and the 2027 litigation budget in the annual report. Active trials require expert witnesses and courtroom teams that cost far more than pre-trial motions.
💲 Other KPIs
Up 1.1% from $84.3 million a year ago and down $0.6 million since the start of the year, with zero debt. Operating cash generation funded the $5.0 million purchase of Orion Medical, $3.0 million in stockholder dividends, and $0.9 million in share buybacks over the first nine months.
Down 0.8% from 3.21 million a year ago, which added 0.9 percentage points to third-quarter earnings per share growth. Utah Medical Products spent $699 thousand to buy back 10,000 shares in the third quarter, bringing nine-month buyback spending to $905 thousand, down 87.7% from $7.36 million a year ago.
Up 6.3% from a year ago and up 12.5% since December, moving in the opposite direction of the 12.1% revenue drop. Customers took an average of 41 days to pay their bills at the end of September, up from 37.5 days in March and 35 days at the end of 2025.
🔮 Guidance
Cut. The company now projects full-year sales to fall about 7% from $38.5 million in 2025, stepping back from its initial goal to offset lost accounts with new biopharma orders. By our math, that full-year plan still leaves fourth-quarter revenue growing about 10.0% from a year ago to $10.0 million, helped by Orion Medical and an easy prior-year comparison.
Cut. Management previously expected legal costs to fall in 2026 under the assumption that no Filshie Clip lawsuit would reach a courtroom. Nine-month legal expenses are already up 16.4% to $1.14 million, and the company now states that cases in two of the four remaining courts will apparently go to trial in 2027.
❓ Key Questions
What caused domestic Filshie Clip sales to drop 45%?
US sales of the contraceptive device grew in the first half of 2026 but fell by $534 thousand to $656 thousand in the third quarter. Investors need to know if hospitals worked down inventory or if doctors are switching to rival procedures.
What are Orion Medical's profit margins and annual run rate?
Utah Medical Products paid $5.0 million for the UK medical supply business, which added $619 thousand of revenue in September. The release did not disclose Orion's gross margin or how much operating profit it contributed after acquisition expenses.
How long will the factory build inventory for biopharma?
Management kept factory staffing unchanged and built inventory by $2.64 million this year while waiting for new biopharma orders that arrived slower than expected. If demand stays slow, the company must choose between writing down stock or cutting production.
How much will the two 2027 Filshie trials cost?
Pre-trial legal defense has cost $1.14 million so far this year across four remaining courts. Taking two of those cases to trial in 2027 will require courtroom teams and could reverse the overhead savings achieved when intangible amortization ended.